Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
All content curated by
Published in Neurology

Journal Scan / Research · January 24, 2022

Real-Life Study Shows Increase in Migraine Days When Erenumab Discontinued After 12 Months

Neurology. Clinical Practice

 

Additional Info

Neurology. Clinical Practice
Erenumab Discontinuation After 12-Month Treatment: A Multicentric, Observational Real-Life Study
Neurol Clin Pract 2021 Dec 01;11(6)e834-e839, F Schiano di Cola, S Caratozzolo, E Venturelli, U Balducci, V Sidoti, E Pari, C Costanzi, A di Summa, GJ Sixt, E D'Adda, P Liberini, R Rao, A Padovani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading